NASDAQ:RGNX - Regenxbio Stock Price, Forecast & News

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio Inc (NASDAQ:RGNX) issued its earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Zacks' consensus estimate of ($0.91) by $0.03. The biotechnology company earned $14.70 million during the quarter, compared to analysts' expectations of $7.46 million. Regenxbio had a negative net margin of 99.57% and a negative return on equity of 18.74%. Regenxbio's quarterly revenue was up 177.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.56) EPS. View Regenxbio's Earnings History.

Regenxbio is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Regenxbio.

6 analysts have issued 12-month target prices for Regenxbio's stock. Their forecasts range from $37.00 to $150.00. On average, they anticipate Regenxbio's stock price to reach $80.80 in the next year. This suggests a possible upside of 83.7% from the stock's current price. View Analyst Price Targets for Regenxbio.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.

News stories about RGNX stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Regenxbio earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Regenxbio.

Some companies that are related to Regenxbio include argenx (ARGX), Repligen (RGEN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Audentes Therapeutics (BOLD) and Denali Therapeutics (DNLI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Visa (V), Amarin (AMRN), Exelixis (EXEL), Square (SQ), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Alibaba Group (BABA) and Intercept Pharmaceuticals (ICPT).

Regenxbio's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.20%), New York State Teachers Retirement System (0.09%), State of Alaska Department of Revenue (0.06%), Prentiss Smith & Co. Inc. (0.03%), Louisiana State Employees Retirement System (0.03%) and Sanders Morris Harris LLC (0.02%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.

RGNX stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, State of Alaska Department of Revenue and NEXT Financial Group Inc. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Olivier Danos, Patrick J Christmas and Vittal Vasista. View Insider Buying and Selling for Regenxbio.

RGNX stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Sanders Morris Harris LLC, New York State Teachers Retirement System, Prentiss Smith & Co. Inc. and IFP Advisors Inc. View Insider Buying and Selling for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $43.98.

Regenxbio has a market capitalization of $1.62 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis. Regenxbio employs 192 workers across the globe.View Additional Information About Regenxbio.

The official website for Regenxbio is http://www.regenxbio.com/.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]